Restless legs syndrome as a cause of sleep disturbances in cancer patients receiving chemotherapy

Andrea Saini, Alfredo Berruti, Luigi Ferini-Strambi, Vincenza Castronovo, Elena Rametti, Piero Luigi Giuliano, Barbara Ramassotto, Rocco Luigi Picci, Manuela Negro, Sara Campagna, Pier Maria Furlan, Luca Ostacoli

Research output: Contribution to journalArticle

Abstract

Context: Sleep disturbances are frequent in cancer patients during chemotherapy; the contributory role of restless legs syndrome (RLS) in this setting has never been assessed. Objectives: This study investigated the role of RLS in causing sleep disturbances and altering the quality of life in cancer patients during chemotherapy. Methods: Evaluation tools included the Pittsburgh Sleep Quality Index (PSQI), the RLS questionnaires, the Functional Assessment of Cancer Therapy-General, and the Hospital Anxiety and Depression Scale for quality of life and anxiety/depression assessment. The study population was 173 cancer patients. The questionnaires were administered during the third chemotherapy cycle. Patients positive for RLS were reassessed six months after the end of chemotherapy. Results: In all, 58.8% of patients reported experiencing sleep disturbances (PSQI ≥ 5) and 20% screened positive for RLS. Neither sleep disturbances nor RLS was associated with anemia, neurotoxic cytotoxic drugs, or benzamide treatment. A direct relationship was found between the PSQI and RLS (P = 0.007); both PSQI and RLS scores were significantly associated with poor quality of life (P = 0.008 and 0.01, respectively) and anxiety (P = 0.0001 and 0.01, respectively). PSQI score also was associated with depression (P = 0.0001). RLS persisted in four of the 25 RLS-positive patients reassessed at six months after chemotherapy. RLS recovery was associated with a significant reduction in sleep disturbances and improvement in quality of life. Conclusion: RLS can be a contributory factor in sleep disturbances in cancer patients undergoing chemotherapy. Screening for RLS could aid in tailoring a potentially more efficacious treatment of such disturbances.

Original languageEnglish
Pages (from-to)56-64
Number of pages9
JournalJournal of Pain and Symptom Management
Volume46
Issue number1
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Restless Legs Syndrome
Sleep
Drug Therapy
Neoplasms
Quality of Life
Anxiety
Depression
General Hospitals
Anemia

Keywords

  • anxiety
  • Cancer
  • chemotherapy
  • depression
  • quality of life
  • restless legs syndrome
  • sleep disturbances

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Nursing(all)

Cite this

Restless legs syndrome as a cause of sleep disturbances in cancer patients receiving chemotherapy. / Saini, Andrea; Berruti, Alfredo; Ferini-Strambi, Luigi; Castronovo, Vincenza; Rametti, Elena; Giuliano, Piero Luigi; Ramassotto, Barbara; Picci, Rocco Luigi; Negro, Manuela; Campagna, Sara; Furlan, Pier Maria; Ostacoli, Luca.

In: Journal of Pain and Symptom Management, Vol. 46, No. 1, 07.2013, p. 56-64.

Research output: Contribution to journalArticle

Saini, A, Berruti, A, Ferini-Strambi, L, Castronovo, V, Rametti, E, Giuliano, PL, Ramassotto, B, Picci, RL, Negro, M, Campagna, S, Furlan, PM & Ostacoli, L 2013, 'Restless legs syndrome as a cause of sleep disturbances in cancer patients receiving chemotherapy', Journal of Pain and Symptom Management, vol. 46, no. 1, pp. 56-64. https://doi.org/10.1016/j.jpainsymman.2012.06.018
Saini, Andrea ; Berruti, Alfredo ; Ferini-Strambi, Luigi ; Castronovo, Vincenza ; Rametti, Elena ; Giuliano, Piero Luigi ; Ramassotto, Barbara ; Picci, Rocco Luigi ; Negro, Manuela ; Campagna, Sara ; Furlan, Pier Maria ; Ostacoli, Luca. / Restless legs syndrome as a cause of sleep disturbances in cancer patients receiving chemotherapy. In: Journal of Pain and Symptom Management. 2013 ; Vol. 46, No. 1. pp. 56-64.
@article{2b5476c81c7648859d1ffbe53669e4b6,
title = "Restless legs syndrome as a cause of sleep disturbances in cancer patients receiving chemotherapy",
abstract = "Context: Sleep disturbances are frequent in cancer patients during chemotherapy; the contributory role of restless legs syndrome (RLS) in this setting has never been assessed. Objectives: This study investigated the role of RLS in causing sleep disturbances and altering the quality of life in cancer patients during chemotherapy. Methods: Evaluation tools included the Pittsburgh Sleep Quality Index (PSQI), the RLS questionnaires, the Functional Assessment of Cancer Therapy-General, and the Hospital Anxiety and Depression Scale for quality of life and anxiety/depression assessment. The study population was 173 cancer patients. The questionnaires were administered during the third chemotherapy cycle. Patients positive for RLS were reassessed six months after the end of chemotherapy. Results: In all, 58.8{\%} of patients reported experiencing sleep disturbances (PSQI ≥ 5) and 20{\%} screened positive for RLS. Neither sleep disturbances nor RLS was associated with anemia, neurotoxic cytotoxic drugs, or benzamide treatment. A direct relationship was found between the PSQI and RLS (P = 0.007); both PSQI and RLS scores were significantly associated with poor quality of life (P = 0.008 and 0.01, respectively) and anxiety (P = 0.0001 and 0.01, respectively). PSQI score also was associated with depression (P = 0.0001). RLS persisted in four of the 25 RLS-positive patients reassessed at six months after chemotherapy. RLS recovery was associated with a significant reduction in sleep disturbances and improvement in quality of life. Conclusion: RLS can be a contributory factor in sleep disturbances in cancer patients undergoing chemotherapy. Screening for RLS could aid in tailoring a potentially more efficacious treatment of such disturbances.",
keywords = "anxiety, Cancer, chemotherapy, depression, quality of life, restless legs syndrome, sleep disturbances",
author = "Andrea Saini and Alfredo Berruti and Luigi Ferini-Strambi and Vincenza Castronovo and Elena Rametti and Giuliano, {Piero Luigi} and Barbara Ramassotto and Picci, {Rocco Luigi} and Manuela Negro and Sara Campagna and Furlan, {Pier Maria} and Luca Ostacoli",
year = "2013",
month = "7",
doi = "10.1016/j.jpainsymman.2012.06.018",
language = "English",
volume = "46",
pages = "56--64",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Restless legs syndrome as a cause of sleep disturbances in cancer patients receiving chemotherapy

AU - Saini, Andrea

AU - Berruti, Alfredo

AU - Ferini-Strambi, Luigi

AU - Castronovo, Vincenza

AU - Rametti, Elena

AU - Giuliano, Piero Luigi

AU - Ramassotto, Barbara

AU - Picci, Rocco Luigi

AU - Negro, Manuela

AU - Campagna, Sara

AU - Furlan, Pier Maria

AU - Ostacoli, Luca

PY - 2013/7

Y1 - 2013/7

N2 - Context: Sleep disturbances are frequent in cancer patients during chemotherapy; the contributory role of restless legs syndrome (RLS) in this setting has never been assessed. Objectives: This study investigated the role of RLS in causing sleep disturbances and altering the quality of life in cancer patients during chemotherapy. Methods: Evaluation tools included the Pittsburgh Sleep Quality Index (PSQI), the RLS questionnaires, the Functional Assessment of Cancer Therapy-General, and the Hospital Anxiety and Depression Scale for quality of life and anxiety/depression assessment. The study population was 173 cancer patients. The questionnaires were administered during the third chemotherapy cycle. Patients positive for RLS were reassessed six months after the end of chemotherapy. Results: In all, 58.8% of patients reported experiencing sleep disturbances (PSQI ≥ 5) and 20% screened positive for RLS. Neither sleep disturbances nor RLS was associated with anemia, neurotoxic cytotoxic drugs, or benzamide treatment. A direct relationship was found between the PSQI and RLS (P = 0.007); both PSQI and RLS scores were significantly associated with poor quality of life (P = 0.008 and 0.01, respectively) and anxiety (P = 0.0001 and 0.01, respectively). PSQI score also was associated with depression (P = 0.0001). RLS persisted in four of the 25 RLS-positive patients reassessed at six months after chemotherapy. RLS recovery was associated with a significant reduction in sleep disturbances and improvement in quality of life. Conclusion: RLS can be a contributory factor in sleep disturbances in cancer patients undergoing chemotherapy. Screening for RLS could aid in tailoring a potentially more efficacious treatment of such disturbances.

AB - Context: Sleep disturbances are frequent in cancer patients during chemotherapy; the contributory role of restless legs syndrome (RLS) in this setting has never been assessed. Objectives: This study investigated the role of RLS in causing sleep disturbances and altering the quality of life in cancer patients during chemotherapy. Methods: Evaluation tools included the Pittsburgh Sleep Quality Index (PSQI), the RLS questionnaires, the Functional Assessment of Cancer Therapy-General, and the Hospital Anxiety and Depression Scale for quality of life and anxiety/depression assessment. The study population was 173 cancer patients. The questionnaires were administered during the third chemotherapy cycle. Patients positive for RLS were reassessed six months after the end of chemotherapy. Results: In all, 58.8% of patients reported experiencing sleep disturbances (PSQI ≥ 5) and 20% screened positive for RLS. Neither sleep disturbances nor RLS was associated with anemia, neurotoxic cytotoxic drugs, or benzamide treatment. A direct relationship was found between the PSQI and RLS (P = 0.007); both PSQI and RLS scores were significantly associated with poor quality of life (P = 0.008 and 0.01, respectively) and anxiety (P = 0.0001 and 0.01, respectively). PSQI score also was associated with depression (P = 0.0001). RLS persisted in four of the 25 RLS-positive patients reassessed at six months after chemotherapy. RLS recovery was associated with a significant reduction in sleep disturbances and improvement in quality of life. Conclusion: RLS can be a contributory factor in sleep disturbances in cancer patients undergoing chemotherapy. Screening for RLS could aid in tailoring a potentially more efficacious treatment of such disturbances.

KW - anxiety

KW - Cancer

KW - chemotherapy

KW - depression

KW - quality of life

KW - restless legs syndrome

KW - sleep disturbances

UR - http://www.scopus.com/inward/record.url?scp=84880304437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880304437&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2012.06.018

DO - 10.1016/j.jpainsymman.2012.06.018

M3 - Article

C2 - 23116590

AN - SCOPUS:84880304437

VL - 46

SP - 56

EP - 64

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 1

ER -